Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

15 Aug 2022

Mydecine Board Members Resign

The departures are part of a larger organizational shift that will allow the corporation to concentrate on its core competencies with more efficiency....

By Microdose NewsDesk

Finance, Industry

15 Aug 2022

atai Life Sciences Secures $175 Million Loan

The new loand plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments...

By Microdose NewsDesk

Industry

12 Aug 2022

Field Trip & Reunion Announce $19.9 Million Private Placement Financing

First day of trading for both Reunion and Field Trip Health & Wellness expected to occur on or about August 17, 2022....

By Microdose NewsDesk

Industry

10 Aug 2022

Microdosing Collective: New Non-Profit Promotes Low-Dose Psychedelics

New Non-Profit Group Promotes Regulated Use of Sub-Perceptible Psychedelics as Legal Wellness Supplements...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

9 Aug 2022

Breaking News: Terran Biosciences Sues Compass Pathways for Stealing Trade Secrets

According to the court filings, Compass allegedly entered into negations and signed an NDA with a researcher regarding psilocybin development, before ending the talks and "milking" him for this confidential...

By Microdose NewsDesk

Finance, Industry

9 Aug 2022

Cybin Announces Financial Results and $35M Equity Program

Cybin has started the week off with several newsworthy stories....

By Microdose NewsDesk

Don’t Miss

8 Aug 2022

News You Might Have Missed: Aug 8th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

5 Aug 2022

MindMed Announces 1:15 Reverse Stock Split

According to the press release: “The reverse share split is intended to enable the Company to achieve several important corporate objectives, give the Company greater flexibility in considering and planning...

By Microdose NewsDesk

Finance

4 Aug 2022

COMPASS Pathways Announces Q2 Results and Highlights

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights...

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.